about
The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications.The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer.The Delayed Risk Stratification System in the Risk of Differentiated Thyroid Cancer Recurrence.99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma.Prevalence of macroprolactinaemia in regularly menstruating women with non-toxic goitre or autoimmune thyroid disease.Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma.Repeated nondiagnostic result of thyroid fine-needle aspiration biopsy.Response to therapy of papillary thyroid cancer of known BRAF status.Colorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Free and bioavailable fractions of sex steroids may influence bones in young men, depending on age and oestradiol level.Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.The usefulness of determining the presence of BRAF V600E mutation in fine-needle aspiration cytology in indeterminate cytological results.Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Comparison of the usefulness of post-ablative and post-operative thyroglobulin concentration measuring in prognostic assessment of patients with differentiated thyroid cancer.Delayed risk stratification system in pT1aN0/Nx DTC patients treated without radioactive iodine.The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish populationThe role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC).Case report of a woman with monoclonal gammapathy and papillary thyroid carcinoma, diagnosed because of detection of CHEK2 (I157T) mutation in genetic examinations.Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma.[Clinical-pathomorphologic preparation of patients after surgical treatment of differentiated thyroid cancer to adjuvant treatment with 131I].Serum interleukin-16 and RANTES during treatment of Graves' orbitopathy with corticosteroids and teleradiotherapy.[Serum levels of 25(OH)D3 in patients with prostate cancer compared to healthy men].Testing new susceptibility genes in the cohort of apparently sporadic phaeochromocytoma/paraganglioma patients with clinical characteristics of hereditary syndromes.Comparing the effectiveness of stimulation using rhTSH and thyroid hormone withdrawal in the treatment of thyroid cancer.Picture of thyroid cancer in 2012.[Percutaneous ethanol injections in the treatment of nodular thyroid disease--fourteen years of experience].Diagnostic performance evaluation of post-operative serum calcitonin (CT) levels as a factor for good prognosis in medullary thyroid carcinoma (MTC).[The POEMS syndrome with coexisting endocrinopathy--case report].Measurement of 131I activity in air indoor Polish nuclear medical hospital as a tool for an internal dose assessment.Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).Iodine-induced hyperthyroidism--an epidemiological survey several years after institution of iodine prophylaxis in Poland.Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update.Variation of the epidemiological structure of thyroid cancer between year 2000 and 2012.Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C.Comparative assessment of calcitonin stimulation test using calcium gluconate and pentagastrin and the usefulness of procalcitonin basic and post-stimulation concentrations in the diagnosis of patients after surgery for medullary.The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.CHEK2 mutations and the risk of papillary thyroid cancer.Neuroendocrine neoplasms of the small intestine and appendix - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).
P50
Q27852737-8204B0CA-66D8-450E-B5B4-5387D8897724Q33821945-4A9460C0-2C5B-40D7-8651-B1A9286C62E0Q35730333-5F17C6DF-D26B-41B6-932A-4BB13DD77B11Q35989876-853C09D5-1D2B-4CFB-89CE-F77A5565863BQ36104200-827EB9AA-4221-43D3-8DDC-3F0670047353Q36523774-38C1AD54-F7D9-4153-889B-FC3C2E087CC6Q36662850-ABEFCD9E-6E7B-44BD-A0A2-CC9FEF808977Q37657690-BB0C269C-08C6-432B-9360-BD4902136E1CQ38674063-9292A673-D2CF-4229-B566-0F888B8D23A8Q38765743-2579A2DD-B90A-4559-8691-28020CFBB0DAQ38765746-4852F19A-AD3E-4925-A723-C38291CF9C30Q39503131-48F6C370-CEDC-4D99-8A0D-F487A0AED56EQ39988308-BEB0F861-30A6-4049-8589-129A132C8AC5Q39992133-18DDCAC8-3A4C-46C8-ACF2-818114E14215Q40186992-C2356028-1869-45ED-9063-3CC4DA1B01FCQ40216508-3667115E-DBB6-4CAF-B2A1-594D6CF2A5CEQ41110411-BDF8C5AD-B9C6-46AA-A728-A9555B9F1F33Q41709550-6FA365ED-6262-4AE1-B905-0BB2CEF637D7Q42479418-76EC22E1-27AC-4E32-8225-DDFA26BB0F41Q42836975-0A5A6573-8F47-47DF-AB9E-D2E7F3479E74Q42943707-5563ABA3-0748-4D01-87BD-E7BC03585A69Q44104602-48F7C3DD-ABE2-4D1C-95A4-D197876D7C56Q44350844-C4968A9D-3E3A-4D24-97C9-666C2297368EQ45111035-DFCD7868-2889-4A6C-9C8D-670819C8E61AQ45428379-4693DB75-422E-4FE3-8F7E-B54F02DED898Q45977788-40337808-92B5-4C7E-8368-7457A2B5DA53Q46271407-80817C92-B1F2-4387-A45D-7DB599C274A5Q46840935-D9CEC2EC-7470-4544-B4AB-1852719DE6A0Q46879923-502EEEBE-F127-4799-8BB6-8336E4446F33Q46946881-D930E414-D880-45B3-A34E-E4A61DC2500FQ47564652-A3BFCF7A-D831-4F53-9BF8-3DB1B1A79524Q47574245-F4C2C5C2-415A-456E-B61A-1C25388214B1Q47893974-FF1BF253-9F48-4A68-BEBA-B4033A793BA1Q50016120-745E5B89-7F0E-411F-8BCB-E067B0BE8AE8Q50285717-9D7F6E9A-3539-4557-8DB3-53E49F8BB718Q50584101-8B63C52B-05ED-4B02-8F0C-35470532899DQ51091406-44471FF5-4180-4460-B31A-F381C050B0C0Q51123318-60BEF792-E47E-4BF1-97AF-E76D0C9B1A54Q52976068-DFE93552-AAC7-496A-BB4B-87C97E13133AQ53269901-0C074528-BE5E-4F7F-A463-7B77B43D7498
P50
description
Pools onderzoekster
@nl
hulumtuese
@sq
researcher
@en
ricercatrice
@it
taighdeoir
@ga
հետազոտող
@hy
name
Aldona Kowalska
@ast
Aldona Kowalska
@ca
Aldona Kowalska
@cs
Aldona Kowalska
@en
Aldona Kowalska
@es
Aldona Kowalska
@ga
Aldona Kowalska
@gl
Aldona Kowalska
@hr
Aldona Kowalska
@hsb
Aldona Kowalska
@it
type
label
Aldona Kowalska
@ast
Aldona Kowalska
@ca
Aldona Kowalska
@cs
Aldona Kowalska
@en
Aldona Kowalska
@es
Aldona Kowalska
@ga
Aldona Kowalska
@gl
Aldona Kowalska
@hr
Aldona Kowalska
@hsb
Aldona Kowalska
@it
altLabel
ALDONA KOWALSKA
@en
prefLabel
Aldona Kowalska
@ast
Aldona Kowalska
@ca
Aldona Kowalska
@cs
Aldona Kowalska
@en
Aldona Kowalska
@es
Aldona Kowalska
@ga
Aldona Kowalska
@gl
Aldona Kowalska
@hr
Aldona Kowalska
@hsb
Aldona Kowalska
@it
P214
P106
P1153
7005603952
P1412
P1559
Aldona Kowalska
@pl
P21
P214
P27
P31
P3124
P496
0000-0001-5647-5898
P734
P735
P7859
viaf-164379469